Mizuho Lifts PT on Medtronic (MDT) to $100 From $98, Keeps an Outperform Rating

Medtronic plc (NYSE:MDT) is one of the top low volatility healthcare stocks to buy now. On July 16, Mizuho raised the firm’s price target on Medtronic plc (NYSE:MDT) to $100 from $98 while keeping an Outperform rating on the shares.

The firm told investors that it adjusted its price targets in the medical devices and diagnostics segment before the Q2 earnings reports.

Medtronic plc (NYSE:MDT) reported results for its fourth quarter and fiscal year 2025, which ended April 25, on May 21. It reported a FY25 revenue of $33.5 billion and adjusted revenue of $33.6 billion, reflecting a 3.6% growth as reported and 4.9% organic.

GAAP diluted EPS for FY25 also rose 31% to $3.61, while non-GAAP diluted EPS increased 6% to $5.49.

Medtronic plc (NYSE:MDT) is a medical technology company that manufactures, distributes, and sells device-based medical services and therapies.

It operates under four primary segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.